Chapter 3: Pharmacodynamics — Module 5: Drug Targets — Enzymes, Transporters, Ion Channels and Nuclear Receptors
1. A 54-year-old man with newly diagnosed CML (chronic myeloid leukemia) in chronic phase is started on imatinib 400 mg daily. After 18 months of excellent molecular response, repeat testing shows loss of major molecular response. BCR-ABL (breakpoint cluster region-Abelson) kinase domain mutation analysis reveals a T315I point mutation. His oncologist switches him to ponatinib. Which of the following best explains why T315I confers resistance to imatinib and dasatinib but not to ponatinib?
A) The T315I mutation increases BCR-ABL kinase activity by 100-fold, producing a signaling intensity that overwhelms the competitive inhibition achievable with imatinib at clinically tolerable doses, requiring a more potent compound
B) T315I causes BCR-ABL to switch from tyrosine kinase to serine/threonine kinase activity -- imatinib and dasatinib are selective for tyrosine kinase domains while ponatinib inhibits both kinase types
C) The T315I mutation causes BCR-ABL to relocate from the cytoplasm to the nucleus, where imatinib and dasatinib cannot penetrate but ponatinib achieves therapeutic concentrations through active nuclear transport
D) T315I eliminates the allosteric binding site that all first- and second-generation TKIs use -- ponatinib is the only agent that binds the ATP-binding active site directly rather than the allosteric site
E) Threonine-315 is the gatekeeper residue in the BCR-ABL ATP-binding pocket -- it forms a critical hydrogen bond with imatinib and dasatinib that is essential for their binding; the T315I mutation replaces the hydrogen bond-donating threonine with isoleucine (which cannot form this hydrogen bond) and introduces a bulky side chain that sterically clashes with imatinib and most second-generation TKIs; ponatinib was specifically designed with a carbon-carbon triple bond that avoids the steric clash with the isoleucine-315 side chain, allowing it to retain binding activity at the T315I mutant
ANSWER: E
Rationale:
The T315I gatekeeper mutation is the prototypical example of targeted therapy resistance through target modification and a model for understanding structure-activity relationships in kinase inhibitor design. Threonine-315 is called the gatekeeper residue because it controls access to a hydrophobic binding pocket adjacent to the ATP-binding site that imatinib occupies. In wild-type BCR-ABL, the hydroxyl group of threonine-315 forms a critical hydrogen bond with imatinib -- this interaction contributes substantially to imatinib's binding affinity. The T315I mutation replaces the small, hydrogen bond-capable threonine with isoleucine, a larger, purely hydrophobic amino acid that cannot form the key hydrogen bond. Furthermore, the bulkier isoleucine side chain introduces steric clashes that prevent imatinib from fitting into its usual binding conformation. Second-generation TKIs (dasatinib, nilotinib, bosutinib) were developed to overcome most BCR-ABL resistance mutations, but they still require a hydrogen bond with the gatekeeper residue and are similarly defeated by T315I. Ponatinib (Iclusig) was rationally designed with a carbon-carbon triple bond that provides a linear, compact geometry at the position corresponding to the gatekeeper -- this unique geometry avoids the steric clash with isoleucine-315 while maintaining interactions with the rest of the binding site. This structure-guided design allowed ponatinib to overcome T315I. The clinical tradeoff is that ponatinib has greater cardiovascular toxicity than earlier TKIs, requiring careful risk-benefit assessment.
Option A: Option A is incorrect -- T315I does not increase kinase activity 100-fold; the resistance is due to drug binding impairment, not enhanced kinase potency.
Option B: Option B is incorrect -- BCR-ABL remains a tyrosine kinase after T315I mutation; the mutation does not alter the kinase class.
Option C: Option C is incorrect -- BCR-ABL localization is not altered by T315I; nuclear transport is not the mechanism of ponatinib selectivity.
Option D: Option D is incorrect -- imatinib and most TKIs bind within the ATP-binding site (in the inactive DFG-out (named for the Asp-Phe-Gly motif in the kinase activation loop) conformation); ponatinib also binds within the ATP-binding site, designed to avoid the specific steric clash at residue 315.
2. A 38-year-old woman with systemic lupus erythematosus has been on hydroxychloroquine and is now started on high-dose methylprednisolone 1 g IV daily for three days for acute lupus nephritis. After treatment she is transitioned to prednisolone 60 mg daily. Over the following six months, despite ongoing anti-inflammatory benefit, she develops hyperglycemia, hypertension, weight gain, moon face, and early osteoporosis. Her rheumatologist explains that these metabolic effects do not diminish over time the way some drug effects do. Which pharmacodynamic principle best explains why glucocorticoid metabolic side effects persist without tachyphylaxis?
A) Chronic high-dose GR (glucocorticoid receptor) activation drives sustained transactivation of metabolic genes -- GR-mediated transcription of gluconeogenic enzymes, adipogenic genes, and genes controlling fat redistribution continues unabated as long as drug is present because metabolic gene transcription through GRE (glucocorticoid response element) binding is not subject to the receptor desensitization or downregulation mechanisms that attenuate many other receptor-mediated effects; the GR does not undergo significant ligand-induced downregulation at therapeutic doses, and the metabolic pathways activated remain fully responsive to continued GR stimulation
B) Prolonged high-dose GR activation drives progressive GR downregulation through beta-arrestin-mediated internalization -- paradoxically, this reduces anti-inflammatory effects but does not reduce metabolic effects because metabolic genes have lower GR occupancy requirements for full activation
C) Prolonged transactivation-driven gene induction causes epigenetic methylation of GRE-containing promoters, locking them in the active state -- metabolic gene expression becomes GR-independent and self-sustaining even if the drug is stopped
D) High-dose methylprednisolone saturates GR in anti-inflammatory pathways within the first three days, after which all subsequent GR activation drives only metabolic effects because anti-inflammatory GR binding sites are irreversibly occupied
E) Long-term glucocorticoid therapy selectively upregulates the GR-beta isoform, which acts as a dominant-negative inhibitor of GR-alpha in anti-inflammatory pathways while paradoxically activating metabolic genes through a GR-beta-specific mechanism
ANSWER: A
Rationale:
Glucocorticoid metabolic side effects are a direct and persistent consequence of continued GR transactivation -- the same nuclear receptor mechanism that underlies the anti-inflammatory effects, but operating in metabolic target tissues. Unlike many drug-receptor systems where tolerance develops through receptor desensitization, internalization, or downregulation (as seen with beta-adrenergic receptors, opioid receptors, or many GPCRs), the glucocorticoid receptor does not undergo significant ligand-induced downregulation at the doses and durations used therapeutically. GR protein levels and DNA-binding activity remain stable during chronic glucocorticoid therapy. The metabolic consequences are therefore the direct, sustained consequence of continued GRE-mediated gene activation: PEPCK (phosphoenolpyruvate carboxykinase) and glucose-6-phosphatase activation drives hepatic gluconeogenesis and hyperglycemia; genes controlling adipocyte differentiation and fat redistribution drive central obesity and moon face; reduced osteoblast activity and increased RANKL (receptor activator of nuclear factor kappa-B ligand) expression drives osteoporosis; mineralocorticoid receptor cross-activation drives hypertension and hypokalemia. None of these metabolic effects attenuates because the receptor remains functional and metabolic gene promoters remain fully responsive to GR activation. This is in contrast to some glucocorticoid effects (such as the euphoric or behavioral effects) that can show some attenuation with chronic use.
Option B: Option B is incorrect -- GR does not undergo significant beta-arrestin-mediated internalization; unlike GPCRs, nuclear receptors are not regulated by GRK (G protein-coupled receptor kinase)/beta-arrestin systems.
Option C: Option C is incorrect -- epigenetic locking of promoters in the active state that becomes GR-independent does not occur as a mechanism of glucocorticoid side effect persistence; effects are drug-dependent.
Option D: Option D is incorrect -- GR binding sites for anti-inflammatory and metabolic effects are not anatomically separate and irreversibly saturable; anti-inflammatory effects persist throughout treatment.
Option E: Option E is incorrect -- while GR-beta does act as a dominant negative inhibitor of GR-alpha and can modulate glucocorticoid sensitivity, it is not selectively upregulated to drive metabolic effects specifically; it actually mediates glucocorticoid resistance when upregulated.
3. A 62-year-old woman with ER (estrogen receptor)-positive, HER2 (human epidermal growth factor receptor 2)-negative early breast cancer completes surgery and radiation and is started on adjuvant tamoxifen 20 mg daily. Her oncologist discusses the benefits and risks of five years of tamoxifen therapy. Which of the following best describes the complete pharmacodynamic profile that underlies both the benefits and the risks of tamoxifen?
A) Tamoxifen is metabolized by CYP2D6 to endoxifen, which has full estrogen receptor agonist activity in breast tissue -- the CYP2D6 activity determines whether tamoxifen is protective or harmful, explaining why CYP2D6 poor metabolizers do not benefit from tamoxifen
B) Tamoxifen competitively blocks estrogen from binding the ER in all tissues equally -- the benefits (breast cancer prevention) and risks (bone loss, cardiovascular risk) both arise from universal ER antagonism
C) Tamoxifen selectively antagonizes ER-alpha but acts as a full agonist at ER-beta -- the uterine stimulation reflects ER-beta activation while the breast cancer protection reflects ER-alpha antagonism; ER-alpha and ER-beta have opposite roles in breast and uterine tissue
D) Tamoxifen is a SERM (selective estrogen receptor modulator) that acts as an ER antagonist in breast tissue (reducing breast cancer cell proliferation and preventing recurrence) and as a partial ER agonist in the uterus (increasing endometrial cancer risk with five-year use by approximately 2-4 fold), bone (maintaining BMD (bone mineral density) and reducing osteoporosis risk), and liver (reducing LDL cholesterol); this tissue-specific pharmacodynamic profile reflects differential co-activator and co-repressor expression across tissues
E) Tamoxifen's uterine stimulation is an off-target effect unrelated to the estrogen receptor -- it activates prostaglandin receptors in the endometrium, producing endometrial proliferation through a pathway pharmacologically distinct from ER signaling
ANSWER: D
Rationale:
Tamoxifen's clinical pharmacology exemplifies the SERM concept -- the same drug binding the same receptor produces fundamentally different pharmacodynamic effects in different tissues. In breast tissue: tamoxifen-ER complex recruits co-repressor proteins (NCoR (nuclear receptor corepressor), SMRT (silencing mediator for retinoid and thyroid receptors)) at estrogen-responsive gene promoters, blocking transcription of proliferative genes (cyclin D1, c-myc). This antagonism reduces breast cancer cell proliferation and, with five years of adjuvant therapy, reduces ipsilateral breast cancer recurrence by approximately 40-50% and contralateral breast cancer risk by approximately 50%. In uterine endometrium: tamoxifen-ER complex recruits co-activator proteins (SRC-1 (steroid receptor coactivator-1), AIB1 (amplified in breast cancer 1)) at endometrial gene promoters, driving proliferative gene expression -- partial agonism. The consequence is increased endometrial cancer risk, approximately 2-4 fold higher than baseline with five years of use; the absolute risk remains low but requires annual surveillance. In bone: tamoxifen-ER complex maintains osteoblast activity and reduces osteoclast activity (partial agonism), reducing bone loss in postmenopausal women and decreasing fracture risk -- a benefit. In liver: tamoxifen-ER complex reduces LDL cholesterol production (partial agonism), providing cardiovascular benefit. This complete profile is what the oncologist must discuss with the patient -- tamoxifen's benefits extend beyond breast cancer prevention but its uterine risk requires monitoring.
Option A: Option A is incorrect -- endoxifen (the active CYP2D6-generated metabolite) has high-affinity ER antagonist activity in breast, not agonist activity; CYP2D6 metabolism is clinically relevant but endoxifen is a more potent antiestrogen, not an agonist.
Option B: Option B is incorrect -- tamoxifen is not a universal ER antagonist; its partial agonist activity in bone and uterus is well-established and clinically important.
Option C: Option C is incorrect -- the tissue-specific SERM behavior of tamoxifen is not explained by ER-alpha vs ER-beta selectivity; both subtypes are present in breast, uterus, and bone; the differential response reflects co-activator/co-repressor expression patterns.
Option E: Option E is incorrect -- endometrial stimulation by tamoxifen is clearly ER-mediated; prostaglandin receptor involvement is not the established mechanism.
4. A 47-year-old man with metastatic non-small cell lung cancer (NSCLC) harboring an EGFR (epidermal growth factor receptor) exon 19 deletion is started on osimertinib. His oncologist explains that osimertinib was specifically designed to overcome the most common resistance mechanism to first-generation EGFR inhibitors (erlotinib, gefitinib). Which of the following best describes osimertinib's mechanism of action and why it overcomes T790M resistance?
A) Osimertinib is a reversible competitive EGFR inhibitor that achieves selectivity for the mutant receptor through a 1000-fold higher binding affinity for EGFR exon 19 deletion versus wild-type EGFR, allowing it to outcompete ATP at mutant EGFR while sparing wild-type receptor at clinically achievable concentrations
B) Osimertinib selectively inhibits EGFR through allosteric binding at the extracellular domain, preventing receptor dimerization -- this mechanism bypasses the intracellular kinase domain where T790M resistance mutations occur
C) Osimertinib is an irreversible covalent EGFR inhibitor that forms a covalent bond with cysteine-797 in the ATP-binding pocket of EGFR; because it forms an irreversible bond, it overcomes the steric effects of the T790M (threonine-to-methionine at codon 790) gatekeeper mutation that reduces the binding of reversible first-generation inhibitors; osimertinib was also designed with an amide group that avoids steric clash with the bulky methionine-790 side chain; additionally, it preferentially inhibits the mutant EGFR (both exon 19 deletion and T790M) over wild-type EGFR, reducing the rash and diarrhea that result from wild-type EGFR inhibition in skin and gut
D) Osimertinib promotes receptor dimerization into an inactive homodimer configuration -- T790M-containing EGFR has enhanced dimerization capacity that first-generation inhibitors cannot overcome because they prevent dimerization, but osimertinib works by promoting rather than preventing dimerization
E) Osimertinib acts as a positive allosteric modulator of EGFR intrinsic GTPase activity, accelerating GTP hydrolysis in the mutant kinase and reducing constitutive EGFR activation through a non-competitive mechanism that is unaffected by T790M gatekeeper mutations
ANSWER: C
Rationale:
Osimertinib (Tagrisso) is a third-generation, irreversible, mutant-selective EGFR inhibitor developed specifically to address T790M-mediated resistance to first-generation EGFR TKIs. First-generation inhibitors (erlotinib, gefitinib) are reversible competitive ATP-site inhibitors that achieve selectivity for EGFR-mutant versus wild-type EGFR primarily through differential affinity. The T790M gatekeeper mutation (threonine-to-methionine at codon 790) introduces a bulky methionine side chain that sterically impairs binding of first-generation inhibitors and additionally restores ATP affinity toward wild-type levels (since threonine-315 in BCR-ABL and threonine-790 in EGFR both form hydrogen bonds with ATP). Osimertinib overcomes T790M through two complementary mechanisms: first, it forms an irreversible covalent bond with cysteine-797 (adjacent to the gatekeeper position) -- irreversible covalent binding sidesteps the affinity competition with the mutant residue; second, it was structurally designed to avoid steric clash with the bulky methionine-790 side chain. Additionally, osimertinib was optimized to preferentially inhibit mutant EGFR (exon 19 deletion, L858R, and T790M-containing forms) relative to wild-type EGFR, producing a more favorable toxicity profile (less rash, less diarrhea from wild-type EGFR inhibition in skin and gut) than earlier generations. Osimertinib is now approved as first-line therapy for EGFR-mutant NSCLC (not just T790M rescue) due to superior PFS (progression-free survival) in the FLAURA (First-Line and Sequential Therapy in Lung Cancer) trial. Note:
Option A: Option A is incorrect -- osimertinib is not reversible; its covalent mechanism is central to its efficacy against T790M.
Option B: Option B is incorrect -- osimertinib is a small molecule targeting the intracellular kinase domain; it does not bind the extracellular domain.
Option D: Option D is incorrect -- osimertinib inhibits EGFR kinase activity; it does not promote dimerization.
Option E: Option E is incorrect -- EGFR is a tyrosine kinase, not a GTPase; it does not hydrolyze GTP.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.